Harel Insurance Investments & Financial Services Ltd. Buys New Shares in Bristol Myers Squibb Company $BMY

Harel Insurance Investments & Financial Services Ltd. purchased a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 9,100 shares of the biopharmaceutical company’s stock, valued at approximately $552,000.

Other hedge funds have also recently made changes to their positions in the company. Swiss RE Ltd. acquired a new stake in Bristol Myers Squibb during the fourth quarter worth approximately $25,000. Physician Wealth Advisors Inc. lifted its position in shares of Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 202 shares during the period. Darwin Wealth Management LLC bought a new position in Bristol Myers Squibb during the second quarter worth $25,000. Bayban bought a new position in Bristol Myers Squibb during the fourth quarter worth $31,000. Finally, EQ Wealth Advisors LLC acquired a new stake in Bristol Myers Squibb in the fourth quarter worth $32,000. 76.41% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on BMY shares. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. Bank of America decreased their price objective on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a report on Friday, July 10th. Citigroup reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a research report on Friday, May 1st. Weiss Ratings reissued a “hold (c+)” rating on shares of Bristol Myers Squibb in a research report on Thursday, July 2nd. Finally, Guggenheim restated a “buy” rating and set a $72.00 price target on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. Eight analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Bristol Myers Squibb currently has an average rating of “Hold” and a consensus price target of $61.25.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The FDA accepted Bristol Myers Squibb’s NDA for mezigdomide in combination therapy for relapsed or refractory multiple myeloma, a meaningful regulatory step that supports the company’s oncology pipeline and future revenue potential. Bristol Myers Squibb (BMY) Wins FDA Review For Mezigdomide In Multiple Myeloma
• Positive Sentiment: Unusually heavy call option buying suggested traders were positioning for further upside in BMY, with call volume well above normal levels.
• Positive Sentiment: Recent coverage highlighted Bristol Myers Squibb as a strong value stock and noted that its earnings surprise history could support another potential beat in the next quarterly report. Here’s Why Bristol Myers Squibb (BMY) is a Strong Value Stock Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: BMY continued to attract investor attention and broad market discussion, which can amplify trading interest even without a specific new catalyst. Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
• Negative Sentiment: Wells Fargo reportedly assigned a Hold rating, and one market note said the stock underperformed peers earlier in the week, which may have tempered some enthusiasm. Bristol-Myers Squibb (BMY) Gets a Hold from Wells Fargo Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors

Bristol Myers Squibb Price Performance

BMY stock opened at $60.47 on Friday. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. The business has a 50-day simple moving average of $56.93 and a two-hundred day simple moving average of $57.76. The company has a market capitalization of $123.48 billion, a P/E ratio of 16.99, a price-to-earnings-growth ratio of 0.17 and a beta of 0.23. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The company had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. During the same quarter last year, the company earned $1.80 earnings per share. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts expect that Bristol Myers Squibb Company will post 6.34 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. The ex-dividend date of this dividend is Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is currently 70.79%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.